Related Experiment Videos
Treatment of gastrointestinal and renal adenocarcinomas with interferon-alpha
L M Meadows1, C Lindley, H Ozer
1Carolina Oncology, Sanford, North Carolina 27330.
Abstract:
Treatment of adenocarcinomas with interferon-alpha as a single agent has been disappointing. Recent efforts have focused on the combination of interferon with cytotoxic drugs such as 5-fluorouracil. A number of postulated mechanisms can explain synergistic interactions between 5-fluorouracil and interferon-alpha, including interaction with pyrimidine pathways, and alteration of drug metabolism. Previous studies in colorectal cancer, using 5-fluorouracil and interferon-alpha are reviewed, suggesting that the combination is more active than 5-fluorouracil alone. In renal cell carcinoma, the literature is reviewed, suggesting that daily interferon is the most efficacious schedule; preliminary data suggest that addition of 5-fluorouracil to interferon-alpha can double the expected response rate of 16% achieved by interferon-alpha alone.
Insights
Combining interferon-alpha with 5-fluorouracil shows promise for treating adenocarcinomas, particularly renal cell carcinoma. This combination therapy appears more effective than interferon-alpha alone, potentially doubling response rates.
Area of Science:
- Oncology
- Pharmacology
Background:
- Single-agent interferon-alpha therapy for adenocarcinomas has yielded disappointing results.
- Combination therapy with cytotoxic drugs is being explored to enhance treatment efficacy.
Purpose of the Study:
- To review existing literature on the combination of 5-fluorouracil and interferon-alpha in treating adenocarcinomas.
- To evaluate the potential synergistic mechanisms and clinical outcomes of this combination therapy.
Main Methods:
- Literature review of studies involving 5-fluorouracil and interferon-alpha in colorectal and renal cell carcinoma.
- Analysis of postulated mechanisms for drug synergy, including pyrimidine pathway interaction and altered drug metabolism.
Main Results:
- Previous studies in colorectal cancer suggest the combination is more active than 5-fluorouracil monotherapy.
- In renal cell carcinoma, preliminary data indicate that adding 5-fluorouracil to interferon-alpha may double the response rate from 16%.
Conclusions:
- The combination of 5-fluorouracil and interferon-alpha demonstrates enhanced activity in adenocarcinomas compared to interferon-alpha alone.
- Further investigation into this combination therapy is warranted for improved cancer treatment outcomes.